(NASDAQ: AKYA) Akoya Biosciences's forecast annual revenue growth rate of 20.49% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.2%.
Akoya Biosciences's revenue in 2024 is $96,633,000.On average, 4 Wall Street analysts forecast AKYA's revenue for 2024 to be $5,674,771,616, with the lowest AKYA revenue forecast at $5,651,184,065, and the highest AKYA revenue forecast at $5,714,182,482. On average, 4 Wall Street analysts forecast AKYA's revenue for 2025 to be $6,768,202,021, with the lowest AKYA revenue forecast at $6,614,342,393, and the highest AKYA revenue forecast at $6,899,112,929.
In 2026, AKYA is forecast to generate $8,259,377,504 in revenue, with the lowest revenue forecast at $7,734,751,059 and the highest revenue forecast at $8,792,701,857.